NCT05293366 LOng COvid COmorbidities: Endocrine,Metabolic,Neuropsychiatric,Muscle,Cardiovascular,Pulmonary,Dermatologic Dysfunctions
| NCT ID | NCT05293366 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Federico II University |
| Condition | Long Covid-19 |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2022-01-27 |
| Primary Completion | 2026-01-27 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2022-01-27 with a primary completion date of 2026-01-27.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Considering the compelling amount of studies focused on patients in the active phase of COVID-19 disease and the scarcity of studies focused on patient cured from disease aimed at evaluating the sequelae of SARS-CoV-2 infection, the purpose of the study is to investigate whether in patients recovered from COVID-19 disease, SARS-CoV-2 infection has induced: 1) endocrine-metabolic function damage; 2) neuro-psychiatric damage; 3) muscle damage; 4) pulmonary damage; 5) cardiological damage; 6) venous vascular damage; 7) dermatological damage. Patients will be evaluated at baseline (at discharge from infectious and/or pneumology unit) and after 3- 12 months. A better definition of the prevalence and type of sequelae after recovery from COVID-19 disease could significantly improve the therapeutic management and long-term follow-up of these patients, with a relevant impact in terms of health resources and public health.
Eligibility Criteria
Inclusion Criteria: * Patients of both sexes recovered from SARS-CoV-2 infection (two negative nasopharyngeal swabs, negative IgM and positive anti SARS-CoV-2 IgG); * Aged over 18 years of age; * Ability to understand protocol procedures Exclusion Criteria: * Any psychological/psychiatric/other medical conditions compromising the understanding of the nature and purpose of the study, and of its possible consequences * uncooperative attitude of the patient
Contact & Investigator
Annamaria Colao, Prof
PRINCIPAL INVESTIGATOR
Federico II University
Frequently Asked Questions
Who can join the NCT05293366 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Long Covid-19. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05293366 currently recruiting?
Yes, NCT05293366 is actively recruiting participants. Contact the research team at colao@unina.it for enrollment information.
Where is the NCT05293366 trial being conducted?
This trial is being conducted at Naples, Italy.
Who is sponsoring the NCT05293366 clinical trial?
NCT05293366 is sponsored by Federico II University. The principal investigator is Annamaria Colao, Prof at Federico II University. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.